Last reviewed · How we verify
Xeglyze (ABAMETAPIR)
At a glance
| Generic name | ABAMETAPIR |
|---|---|
| Sponsor | Hatchtech |
| Target | C-C chemokine receptor type 5 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 2020 |
Approved indications
- Pediculosis capitis
Common side effects
- Erythema
- Rash
- Scalp Erythema/Edema
- Skin burning sensation
- Contact dermatitis
- Vomiting
- Eye irritation
- Eye Irritation
- Scalp Pruritus
- Hair color changes
- Pruritus
Key clinical trials
- Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion (PHASE1)
- Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers (PHASE1)
- Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation (PHASE2)
- A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation (PHASE3)
- Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation (PHASE3)
- A Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of Head Lice Infestation (PHASE2)
- Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xeglyze CI brief — competitive landscape report
- Xeglyze updates RSS · CI watch RSS
- Hatchtech portfolio CI